gilead yeztugo - Search News

News

FDA, HIV and Gilead

Benzinga · 15h

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

ConsumerAffairs · 16h

FDA approves twice-yearly injection for HIV prevention

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Pa

Mint on MSN · 1d

Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know…

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent effectiveness in trials. Here's how it works, and what it costs.

Stocktwits on MSN1d

Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...

3h

Trials for new HIV prevention drug showed 99.9% of participants remained negative

The U.S. Food and Drug Administration has approved a new HIV prevention medication that's been found to be highly effective.

1d

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Fierce Pharma2d

FDA signs off on Gilead’s landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results